- Home
- / PhaseBio Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PhaseBio Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-09-17
Market Capitalization
$3.4 M
2023-01-04
Revenue
$10.8 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|
| Revenue | 668.0K | 2.4M | 320.0K | 10.8M | ||
| General and administrative expense | 2.1M | 2.3M | 4.9M | 11.2M | 13.1M | 16.1M |
| Operating expense total | 9.5M | 8.5M | 20.3M | 42.1M | 85.2M | |
| EBIT | (9.5M) | (8.5M) | (19.6M) | (39.7M) | (84.9M) | (107.4M) |
| EBIT margin, % | -2940.7% | -1683.0% | -26517.5% | |||
| Interest income | 29.0K | 52.0K | 387.0K | 1.6M | 237.0K | 14.0K |
| Interest expense | 2.7M | 3.9M | ||||
| Pre tax profit | (39.2M) | (98.6M) | (129.5M) | |||
| Income tax expense | 1.6M | |||||
| Net Income | (9.2M) | (10.2M) | (23.8M) | (39.2M) | (98.6M) | (131.1M) |